Source: yahoo_news
Source ID: yahoo:938ad5d0982aa5e9e07f3da7c2250a01:SNDX
URL: https://finance.yahoo.com/healthcare/articles/syndax-announces-topline-results-maxpire-200100431.html?.tsrc=rss
Symbol: (SNDX)
Published: 2026-10-12 16:01:00 EDT
Time precision: minute
Title: Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

– Trial did not meet the primary endpoint of annualized rate of FVC decline – – Axatilimab was well tolerated with a safety profile comparable to placebo; no new safety signals were observed – – Axatilimab continues to advance in multiple trials in cGVHD with results expected later this year and early 2028 – NEW YORK, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not